943 related articles for article (PubMed ID: 31182533)
1.
Kim DH; Jhun BW; Moon SM; Kim SY; Jeon K; Kwon OJ; Huh HJ; Lee NY; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182533
[TBL] [Abstract][Full Text] [Related]
2.
Pang Y; Zheng H; Tan Y; Song Y; Zhao Y
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242674
[TBL] [Abstract][Full Text] [Related]
3.
Yu X; Gao X; Li C; Luo J; Wen S; Zhang T; Ma Y; Dong L; Wang F; Huang H
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31138571
[TBL] [Abstract][Full Text] [Related]
4.
Luo J; Yu X; Jiang G; Fu Y; Huo F; Ma Y; Wang F; Shang Y; Liang Q; Xue Y; Huang H
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760127
[TBL] [Abstract][Full Text] [Related]
5.
Brown-Elliott BA; Wallace RJ
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30509936
[TBL] [Abstract][Full Text] [Related]
6.
Kim DH; Kim SY; Koh WJ; Jhun BW
Antimicrob Agents Chemother; 2021 Jun; 65(7):e0230620. PubMed ID: 33903101
[TBL] [Abstract][Full Text] [Related]
7. Targeting bedaquiline mycobacterial efflux pump to potentially enhance therapy in
Martin A; Bouyakoub Y; Soumillion K; Mantu EON; Colmant A; Rodriguez-Villalobos H
Int J Mycobacteriol; 2020; 9(1):71-75. PubMed ID: 32474492
[TBL] [Abstract][Full Text] [Related]
8. Verapamil Improves the Activity of Bedaquiline against Mycobacterium abscessus In Vitro and in Macrophages.
Viljoen A; Raynaud C; Johansen MD; Roquet-Banères F; Herrmann JL; Daher W; Kremer L
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31209005
[TBL] [Abstract][Full Text] [Related]
9. A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria.
Ruth MM; Sangen JJN; Remmers K; Pennings LJ; Svensson E; Aarnoutse RE; Zweijpfenning SMH; Hoefsloot W; Kuipers S; Magis-Escurra C; Wertheim HFL; van Ingen J
J Antimicrob Chemother; 2019 Apr; 74(4):935-943. PubMed ID: 30649327
[TBL] [Abstract][Full Text] [Related]
10. Biofilm prevention concentration of clarithromycin against clinically relevant species of nontuberculous mycobacteria.
Senhaji-Kacha A; Akir A; Broncano-Lavado A; Esteban J
Rev Esp Quimioter; 2024 Jun; 37(3):266-269. PubMed ID: 38602224
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of bedaquiline against slow-growing nontuberculous mycobacteria.
Martin A; Godino IT; Aguilar-Ayala DA; Mathys V; Lounis N; Villalobos HR
J Med Microbiol; 2019 Aug; 68(8):1137-1139. PubMed ID: 31210631
[TBL] [Abstract][Full Text] [Related]
12.
Sun Q; Liao X; Wang C; Jiang G; Yang J; Zhao J; Huang H; Wang G; Li H
J Med Microbiol; 2022 Jun; 71(6):. PubMed ID: 35708979
[No Abstract] [Full Text] [Related]
13. Determination of MIC Distribution and Mechanisms of Decreased Susceptibility to Bedaquiline among Clinical Isolates of Mycobacterium abscessus.
Li B; Ye M; Guo Q; Zhang Z; Yang S; Ma W; Yu F; Chu H
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29712658
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria.
Mougari F; Loiseau J; Veziris N; Bernard C; Bercot B; Sougakoff W; Jarlier V; Raskine L; Cambau E;
J Antimicrob Chemother; 2017 Jun; 72(6):1669-1677. PubMed ID: 28333340
[TBL] [Abstract][Full Text] [Related]
15.
Brown-Elliott BA; Wallace RJ
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0068922. PubMed ID: 35943269
[TBL] [Abstract][Full Text] [Related]
16.
Schulthess B; Akdoğan Kittana FN; Hömke R; Sander P
Antimicrob Agents Chemother; 2022 May; 66(5):e0234621. PubMed ID: 35420492
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of bedaquiline against rapidly growing nontuberculous mycobacteria.
Aguilar-Ayala DA; Cnockaert M; André E; Andries K; Gonzalez-Y-Merchand JA; Vandamme P; Palomino JC; Martin A
J Med Microbiol; 2017 Aug; 66(8):1140-1143. PubMed ID: 28749330
[TBL] [Abstract][Full Text] [Related]
18. Sudapyridine (WX-081) antibacterial activity against
Zheng L; Wang H; Qi X; Zhang W; Wang B; Fu L; Chen X; Chen X; Lu Y
mSphere; 2024 Feb; 9(2):e0051823. PubMed ID: 38240581
[TBL] [Abstract][Full Text] [Related]
19. Omadacycline drug susceptibility testing for non-tuberculous mycobacteria using oxyrase to overcome challenges with drug degradation.
Boorgula GD; Gumbo T; Singh S; McShane PJ; Philley JV; Srivastava S
Tuberculosis (Edinb); 2024 Jul; 147():102519. PubMed ID: 38754247
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in molecular diagnostics and understanding mechanisms of drug resistance in nontuberculous mycobacterial diseases.
Huh HJ; Kim SY; Jhun BW; Shin SJ; Koh WJ
Infect Genet Evol; 2019 Aug; 72():169-182. PubMed ID: 30315892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
